The drugmaker raised full-year guidance after posting $1.2 billion in Q2 revenue, up 16% year-over-year.
Jazz Pharmaceuticals raised its 2026 revenue forecast to a range of $4.60 billion to $4.75 billion following a record Q2 performance. The company reported $1.2 billion in revenue for the quarter, marking a 16% increase from the same period last year.
The updated guidance reflects strong momentum in Jazz’s existing portfolio and anticipation of the upcoming PDUFA date for zanidatamab on August 25. Prior to this quarter, the company had not provided a specific revenue target for 2026, focusing instead on near-term growth metrics.
Management attributed the growth to robust demand across key therapeutic areas, particularly in oncology and neuroscience. The raised outlook underscores confidence in both organic growth and pipeline advancements.